What does this research mean for the field?

Organizing triple-negative breast cancer therapies through a three-layer framework of tumor-intrinsic vulnerabilities, the local microenvironment, and host-level systemic modifiers better integrates biological interactions for precision treatment selection. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To synthesize current and emerging treatment options for triple-negative breast cancer using a three-layer biological framework to guide precision oncology.

August 29, 2026Journal of Hematology & OncologyOpen Access

Current and future therapies for triple-negative breast cancer

View Full Paper

Ask AI

Bookmark

Authors

ZWZi-Xun WangShanghai Medical College of Fudan University XLXiyu LiuShanghai Jiao Tong University YWYu‐Xiao WuShanghai Medical College of Fudan University

Discussion

Member takes

Implication

Review outlines a multilayered therapeutic framework in triple-negative breast cancer, highlighting biomarker-driven strategies for durable disease control.

Key Points

To synthesize current and emerging treatment options for triple-negative breast cancer using a three-layer biological framework to guide precision oncology.
Structured therapeutic approaches across three interconnected biological levels: tumor-cell-intrinsic vulnerabilities, the local immune/stromal microenvironment, and host-level systemic modifiers.
Categorized interventions by clinical maturity, evaluating evidence level, disease stage, biomarker reliability, and patient tolerance.
Standard-of-care treatments include cytotoxic chemotherapy, immune checkpoint blockade, antibody-drug conjugates, and PARP inhibitors in biomarker-selected patient populations.
Investigational and maturing modalities include pathway-directed kinase inhibitors, epigenetic modulators, cell therapies, cancer vaccines, and microbiome interventions guided by liquid biopsy and AI-driven multiomics.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a9299088e5d7d1fc0c10b9e https://doi.org/10.1186/s13045-026-01839-x

View Full Paper

Ask AI

Bookmark

August 29, 2026Journal of Hematology & OncologyOpen Access

Current and future therapies for triple-negative breast cancer

View Full Paper

Ask AI

Bookmark

Authors

ZWZi-Xun WangShanghai Medical College of Fudan University XLXiyu LiuShanghai Jiao Tong University YWYu‐Xiao WuShanghai Medical College of Fudan University

Discussion

Member takes

Implication

Review outlines a multilayered therapeutic framework in triple-negative breast cancer, highlighting biomarker-driven strategies for durable disease control.

Key Points

To synthesize current and emerging treatment options for triple-negative breast cancer using a three-layer biological framework to guide precision oncology.
Structured therapeutic approaches across three interconnected biological levels: tumor-cell-intrinsic vulnerabilities, the local immune/stromal microenvironment, and host-level systemic modifiers.
Categorized interventions by clinical maturity, evaluating evidence level, disease stage, biomarker reliability, and patient tolerance.
Standard-of-care treatments include cytotoxic chemotherapy, immune checkpoint blockade, antibody-drug conjugates, and PARP inhibitors in biomarker-selected patient populations.
Investigational and maturing modalities include pathway-directed kinase inhibitors, epigenetic modulators, cell therapies, cancer vaccines, and microbiome interventions guided by liquid biopsy and AI-driven multiomics.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a9299088e5d7d1fc0c10b9e https://doi.org/10.1186/s13045-026-01839-x

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark